WRAIR Experimental Therapeutics
Experimental Therapeutics (ET) is a drug discovery and development enterprise created to protect military personnel from death, disease, and injury and meet Army and DOD mission requirements. While its historical focus has been radioprotection and parasitic disease, ET applies its core competencies of medicinal, synthetic, and analytical chemistry as well as clinical pharmacology to all therapeutic areas within the Medical Research and Development Command's portfolio. ET has a 75-year legacy of excellence in small molecule drug development, with over 65 Investigational New Drug (IND) applications submitted to the U.S. Food and Drug Administrations (FDA). ET is a world leader in malaria drug development—every malaria prophylaxis drug was either created by ET scientists or transited ET test systems on its way to FDA approval. ET recently established a robust antibacterial product development effort mandated by the Presidential Combating Antibiotic Resistant Bacteria (CARB) initiative. Februray 14th, 2023.